Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Peptide degradation, storage and cold chain

Name: Peptide degradation, storage and cold chain
Published: 2026-10-27

How peptides break down and why storage claims need product-specific data

Evidence verdict: General degradation chemistry is well established; storage limits for any specific unapproved product are generally unknown.

Last reviewed: Oct 27, 2026

In 30 seconds

Peptides can degrade by hydrolysis, oxidation, deamidation and aggregation. Heat, moisture, light and repeated temperature cycling speed this up. [Lab]
Approved products have stability data and storage instructions on the label. Unapproved products usually do not. [Regulatory]
Aggregates and degradation products matter for safety as well as potency, because they can raise immunogenicity risk; FDA cites aggregation for ipamorelin. [Regulatory]
USP <797> assigns beyond-use dates to compounded sterile preparations; there is no equivalent for research products.

How peptides degrade

Common pathways are peptide-bond hydrolysis, oxidation of methionine, cysteine or tryptophan, deamidation of asparagine and glutamine, and physical aggregation. Rates are sequence- and formulation-specific. [Lab; general pharmaceutical chemistry; no single review cited here, so specific rates are UNVERIFIED]

Lyophilized versus in solution

Freeze-dried powders are generally more stable than solutions, but stability still depends on residual moisture, excipients and storage. Once dissolved, many peptides degrade faster. No dissolution or handling instructions are given here.

Why it is a safety issue

FDA's safety-risk page says compounded ipamorelin acetate may pose immunogenicity risk "due to the potential for aggregation", and lists peptide-related impurities as a concern for BPC-157 and others (FDA safety-risk page). [Regulatory] Reviews of synthetic peptide impurities make the same point about new T-cell epitopes (PMID 37467878). [Review]

Cold chain

Approved peptide products specify storage temperatures and how long they can be kept out of the fridge. A product shipped without temperature control, or with no stated stability data, cannot be assumed to match its label (UNVERIFIED for any specific product).

Standards

USP <797> sets beyond-use dating for compounded sterile preparations based on conditions of preparation and storage. [Regulatory]

Evidence levels used on this page

[Regulatory] FDA, USP or WADA primary document. [Controlled study] randomized trial or systematic review of trials. [Observational] market surveillance, pharmacovigilance or cohort data. [Lab] cell, analytical or animal work. [Case] single case report.

How to read a peptide COA, Immunogenicity and anti-drug antibodies

References

US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 04/22/2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
De Groot AS, et al. Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discov Today. 2023. PMID 37467878.
United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations. https://www.usp.org/compounding/general-chapter-797

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.